28th Jun 2019 12:01
(Alliance News) - Immupharma PLC on Friday reported analysis of the results from the study of Lupuzor, its lead programme for the potential breakthrough compound for Lupus, a potentially life threatening auto-immune disease.
The drug discovery and development company said 62 eligible patients were enrolled throughout the US and Europe completing a 24 week treatment period.
Immupharma said primary endpoint was successfully achieved confirming the safety profile of Lupuzor, with no "serious adverse events" reported.
"We are delighted that Lupuzor has again confirmed its robust safety profile and we are confident that Lupuzor has the potential to bring a much needed treatment to Lupus sufferers around the world," said Chair Tim McCarthy.
"With the positive outcome of this open label extension study with Lupuzor having met its primary endpoint and confirming the robust safety profile of the drug, we continue in our discussions with our regulatory experts and potential partners with the key focus of moving Lupuzor forward," added Chief Scientific Officer Robert Zimmer.
Immupharma shares were trading 16% lower on Friday in London at 11.30 pence each.
Related Shares:
Immupharma